Xencor XmAb23104 (Advanced Solid Tumors) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if an experimental drug, XmAb23104, is safe and effective against your cancer when given with and without the drug Ipilimumab.

What is the Condition Being Studied?

Advanced solid tumors that have gotten worse after treatment with standard cancer therapies or for which there are no available therapies.

Who Can Participate in the Study?

Adults with advanced solid tumors who:
- Have cancer that has gotten worse after treatment with standard therapies
- Have no remaining treatment options

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Have an infusion of the study drug (XmAb23104) on days 1 and 15 of a 28-day cycle
- Potentially have three infusions of the drug ipilimumab (once every three weeks) through the first 2 cycles
- Provide old or new tumor tissue
- Have an eye exam
- Have physical exams, blood and urine tests
- Have imaging scans (CT and/or MRI)
- Have tests of your heart (ECG)

Study Details

Full Title
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects with Selected Advanced Solid Tumors (DUET-3)
Principal Investigator
Protocol Number
IRB: PRO00102372
NCT: NCT03752398
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698